CD8+ T cell exhaustion and cancer immunotherapy

Cancer Lett. 2023 Apr 10:559:216043. doi: 10.1016/j.canlet.2022.216043. Epub 2022 Dec 27.

Abstract

Immunotherapy plays an increasingly important role in the treatment of most malignant tumors, and CD8+ T cells are the most important antitumor effector cells in the process of immunotherapy, and their number and functional status largely determine the antitumor effect. However, under continuous antigen exposure and the stimulation of inflammatory factors, CD8+ T cells gradually show a weakened proliferation and effector function, accompanied by the expression of a variety of inhibitory receptors. This state is known as CD8+ T cell "exhaustion" and often leads to the loss of control and progression of tumors. Recent studies provided us a better understanding of the mechanisms of T cell exhaustion, this review provides an overview of the activation, exhaustion mechanisms and exhaustion characteristics of CD8+ T cells. Although immunotherapy can reverse the exhaustion of CD8+ T cells and significantly improve the antitumor effects, single immunotherapy often has limitations, and it is difficult to achieve satisfactory antitumor effects, therefore, this review also summarizes up-to-date information related to cancer immunotherapy, and these emerging insights provide promising clues to the future management of malignant tumors.

Keywords: Combination immunotherapy; Exhausted T cells; Immunosuppressive microenvironment.

Publication types

  • Review

MeSH terms

  • CD8-Positive T-Lymphocytes*
  • Humans
  • Immunotherapy
  • Neoplasms* / pathology
  • T-Cell Exhaustion